MedTrace Logo

ACT for the Home Management in Malagasy Children

NCT00612547 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2009-02-26

No results posted yet for this study

Summary

The purpose of this study is to assess the feasibility, the acceptability and the effectiveness of the use of the Artesunate + Amodiaquine Fixed Dose Combination for the home management of presumed malaria in Malagasy children by the community-based service providers.

Conditions

  • Fever
  • Suspected Malaria

Interventions

DRUG

Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam)

Tablet: Children aged between 2 and 11 months: Artesunate 25 mg + Amodiaquine 67.5 mg et Children aged between 12 and 59 months: Artesunate 50 mg + Amodiaquine 135 mg Per os one intake per day/3 day

Sponsors & Collaborators

  • Population Services International

    collaborator OTHER

  • Reggio Terzo Mondo

    collaborator UNKNOWN

  • Santé Net

    collaborator UNKNOWN

  • Inter Aide Santé,

    collaborator UNKNOWN

  • Adventist Development and Relief Agency

    collaborator OTHER

  • SAF FJKM

    collaborator UNKNOWN

  • Sanofi

    collaborator INDUSTRY

  • Institut Pasteur de Madagascar

    collaborator OTHER

  • National Malaria Control Programme, Madagascar

    lead OTHER_GOV

Principal Investigators

  • Benjamin Ramarosandratana, MD · National Malaria Control Programme

Eligibility

Min Age
2 Months
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00612547 on ClinicalTrials.gov